Business Wire

Medidata and Bioforum Bolster Decade-Long Relationship to Advance Clinical Data and Biometric Solutions for Clinical Trials

Share

Expanded collaboration leverages Clinical Data Studio and AI-driven biometrics to deliver high-quality, efficient data services for Bioforum’s clients

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that serves clinical trial sponsors worldwide.

Building on more than a decade of collaboration, the expanded partnership provides Bioforum’s biotech customers with broader access to Medidata’s AI-powered technology, enabling a more agile clinical development experience. In addition to Medidata solutions such as Medidata Rave EDC and Medidata Rave RTSM, which Bioforum has leveraged to deliver 60 studies across a range of therapeutic areas, the CRO is adding Medidata Clinical Data Studio and Medidata eConsent to streamline data flow, maintain data integrity, and ensure compliance.

“With our team of experts, industry-leading biometric services, and proprietary technology, Bioforum empowers sponsors to seamlessly manage their clinical data in one place and ensure it’s secure, accurate, and ready for analysis,” said Amir Malka, CEO and co-founder of Bioforum. “We’re excited to be strengthening our alliance with Medidata and, together, providing our customers with the adaptability and advanced solutions they need to thrive.”

“Our expanded partnership with Bioforum brings AI-driven clinical trial management to agile biotech start-ups, accelerating their path to market,” said Janet Butler, executive vice president, head of global sales, Medidata. “By harnessing our Patient Data Surveillance and RBQM platforms, we’re delivering improved operational efficiency for Bioforum and seamless, high-quality data access for their clients.”

Bioforum will sponsor Medidata’s upcoming NEXT New York, a leading clinical trials conference hosted by the company, scheduled for November 13 to 14 in New York City.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

About Bioforum the Data Masters

Bioforum the Data Masters is a leading global clinical research organization (CRO) that specializes in biometric services and solutions for the pharmaceutical, biotech and medical device industries. With a team of experienced professionals and state-of-the-art technology, Bioforum provides a range of services including data management, biostatistics, statistical programming and medical writing to help companies bring new drugs and therapies to market faster. To learn more about us and our services, visit www.bioforumgroup.com or find us on LinkedIn at https://il.linkedin.com/company/bioforum-ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112963841/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Allianz Announces Excellent Performance and Is Fully on Track for Full-year Ambitions7.8.2025 07:13:00 CEST | Press release

2Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806235547/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Allianz achieves strong growth and record operating profitTotal business volume rises 8.01 percent to 44.5 billion euros, supported by good growth across all segments Operating profit increases 12.2 percent and reaches a record level of 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 17.3 percent and reaches 3.0 billion euros. Adjusted for the 0.3 billion euros disposal gain on the UniCredit Joint Venture, shareholders’ core net income increases 7.1 percent 6M 2025 Excellent performance across our businesses and record operating profitTotal business volume grows 10.1 1 percent and reaches 98.5 billion euros, with contributions from all segments Operating profit increases 9.3 percent to 8.6 billion euros, our highest half-

New pulp mill boosts Suzano's sales and revenue in the second quarter of 20257.8.2025 04:17:00 CEST | Press release

Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2025 (2Q25), reporting sales of 3.7 million tonnes of pulp and paper. Sales increased 28% over the same period in 2024 (2Q24), mainly reflecting the strong operational contribution of the new Ribas do Rio Pardo pulp mill, whose production started in July 2024. Net revenue in the quarter totaled R$13.3 billion, a 16% increase compared to 2Q24. The expansion of pulp production capacity in Brazil, combined with the positive contribution to paper sales from the mills recently acquired in the United States and favorable FX rates, mitigated the impact on net revenue of lower pulp prices in the global market compared to 2Q24. As a result, Suzano's adjusted EBITDA reached R$6.1 billion and operating cash generation totaled R$4.1 billion. Net profit totaled R$5.0 billion positively impacted by the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. Beto

Graanul - Update on the Consent Solicitation and Scheme Solicitation6.8.2025 22:22:00 CEST | Press release

Graanul: Update on the Consent Solicitation and Scheme Solicitation relating to: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and together with its subsidiaries, “Graanul”

Statement by Aviator LLC6.8.2025 16:18:00 CEST | Press release

Company successfully initiates proceedings following Georgian court victories; UK injunction preserves status quo pending trial Aviator LLC today issued a statement clarifying the nature and scope of a recent UK court ruling following public statements made by SPRIBE OU regarding interim injunction proceedings. According to Nikoloz Gogilidze, legal representative for Aviator LLC, the recent court order was an interim injunction with limited scope and commercial impact. Gogilidze highlights the key points of the proceedings, which appear to have been mischaracterized in some media reports. Nature of the Court Order: The ruling represents an interim injunction granted at a preliminary procedural stage, not a final determination on the merits of the underlying dispute. Such orders are designed to maintain the status quo pending full trial proceedings. Commercial Impact: The injunction has no practical effect as neither Aviator LLC nor its IP rights licensee had any existing plans to enter

Lenovo Brings Its Biggest-Ever Global Tech World Event to CES 2026 With an Immersive Experience at Sphere in Las Vegas6.8.2025 15:05:00 CEST | Press release

Lenovo Chairman and CEO Yuanqing Yang to deliver CES keynote on smarter AI for all at iconic venue, showcasing innovations with FIFA, Formula 1®, and a host of others at the world’s biggest tech event.Tech World CES Keynote to showcase Lenovo’s role as An Official Technology Partner of Sphere Studios Lenovo (HKSE: 992) (ADR: LNVGY) and Sphere Entertainment Co. (NYSE: SPHR) announced today that, for the first time ever, Lenovo’s annual global innovation event, Tech World, will take center stage at Sphere in Las Vegas on the opening day of CES® 2026. The 11th annual Tech World will feature Lenovo Chairman and CEO Yuanqing Yang’s CES keynote along with Lenovo’s latest product launches, innovations, proofs of concept, and the company’s AI-driven innovation strategy for the coming years. The event at Sphere, which will showcase content created exclusively for Lenovo by Sphere Studios, Sphere’s in-house immersive content studio, marks the second consecutive year that a CES keynote will be de

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye